Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

20/25

Growth 5 Margin 4 Expansion 4 Platform 2 Financial 5

latest quarter score

Earnings Reports

20
Teva (TEVA) Q2 2026: Innovative Portfolio Jumps 43%, Accelerating Biopharma Transformation
July 29, 2026
19
Teva (TEVA) Q1 2026: Innovative Portfolio Jumps to 20% of Sales, Accelerating Gross Margin Expansion
April 29, 2026
21
Teva (TEVA) Q4 2025: Innovative Portfolio Jumps 35%, Accelerating Biopharma Transformation
January 28, 2026
20
Teva (TEVA) Q3 2025: Innovative Portfolio Surges 33%, Sharpening $700M Margin Expansion Path
November 05, 2025
20
Teva (TEVA) Q2 2025: Innovative Portfolio Lifts Guidance by $95M Amid Generics Softness
July 30, 2025
20
Teva (TEVA) Q1 2025: Innovative Brands Jump 45% as Margin Expansion Targets Accelerate
July 07, 2025

Browse all companies